• Exploding research volume: 75,000+ intervention studies for Alzheimer’s alone; hundreds of new longevity papers released every week.

• Multiscale complexity: Longevity spans molecular → cellular → systemic → behavioral levels — each with distinct data types, models, and methodologies.

• Integration bottleneck: Capturing cross-scale interactions (e.g., interventions, biomarkers, pathways) requires laborious manual synthesis of rapidly evolving data.

• Ephemeral insights: By the time datasets and findings are integrated, new studies emerge, deprecating much of the previous effort.

Bottom line: Unlocking and unifying this multiscale data could drastically accelerate discovery across the longevity industry.

The world’s first platform for human biology networks that continuously update with every new discovery, modeling biology across all scales to accelerate breakthroughs in longevity and health.

• Pharma co-development: Partner with pharmaceutical companies; earn profit shares from drugs developed using our platform.

• Lifestyle optimization SaaS: Subscription model for wellness companies or consumers — personalize and visualize network effects of lifestyle interventions.

• Investor intelligence tool: Neutral analytics platform helping investors evaluate biotech pitches, verifying that off-target risks are properly addressed.